Cullinan says REZILIENT3 interim data for zipalertinib plus chemotherapy in EGFR exon 20 NSCLC lands IASLC WCLC 2026 Presidential Symposium slot
CGEM•REZILIENT3 interim data to be presented at IASLC WCLC 2026
Cullinan Therapeutics flagged planned interim results from the Phase 3 REZILIENT3 trial for future presentation at IASLC WCLC 2026.
The study tests zipalertinib with chemotherapy versus chemotherapy alone as first-line treatment for EGFR exon 20 insertion-positive NSCLC.
Selection for the conference’s Presidential Symposium signals the data could be clinically meaningful, with potential to influence treatment practice.
The presentation is scheduled for Sept. 14, 2026, in Seoul.
